In this online CME self-learning activity:
Osteoporosis is characterized by low bone mass and deterioration of bone tissues, which leads to an increased risk of skeletal fractures. Although generally considered a women’s health issue, osteoporosis in men is an important public health issue. ~1- 2 million men in the United States have been estimated to have clinical osteoporosis, and an additional 8 - 13 million men identified to have low bone mass. Despite osteoporosis being frequently overlooked in this population,men account for 29% of the total osteoporotic fractures in the United States and 25% of the total cost of treatment.Morbidity and mortality associated with fracture are higher in men than women, with almost a three-times higher mortality rate associated with hip fracture.However, despite the significant implications for men’s health, male osteoporosis remains largely overlooked. One study found that less than 9% of men 70 years of age or older reported being screened for osteoporosis, and only two-thirds of physicians reported regularly screening men for osteoporosis.
The following healthcare professionals: Primary care physicians and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with male osteoporosis.
Commercial Support Disclosure: This activity is supported by an educational grant from Radius Pharmaceuticals.
Learners may participate in this activity free of charge.
Release Date: May 23, 2020 -- Expiration Date: May 23, 2022
Faculty: Azeez Farooki, MD
Faculty introduction, disclosures
Introduction content: Cursory review of male osteoporosis and fracture assessment
Preventing secondary fracture in men with osteoporosis
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201861254
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Azeez Farooki, MD, Associate Attending Physician, Endocrinology Service, MSKCC, has no relevent financial disclosures.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Postmenopausal osteoporosis risk stratification and treatment of those at high risk for fracture
The current and emerging landscape of pediatric growth hormone deficiency (GHD) pharmacotherapy
Hypoparathyroidism: Optimizing pharmacotherapeutic management strategies